The group's principal activity is to do research, develop and validate a new class of drugs based upon it's patented and proprietary electrolysis technologies. The group is developing active anti-viral, anti-bacterial and anti-fungal agents for a variety of applications. Mdi-p is a product developed by the group to destroy certain viruses, bacteria, pathogenic fungi, parasites and other infectious agents. The product may be used as a sterilizing agent for medical and dental instruments. Mdi-p may also potentially be used to remove or inactivate infectious agents in human and animal blood-derived products such as plasma and gamma globulin. The group is in the development stage.
